Altimmune Chief Scientific Officer To Present At Two Premier Vaccine Conferences

GAITHERSBURG, MD--(Marketwired - October 12, 2015) - Altimmune, Inc. (formerly Vaxin Inc.), a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis, B. ceres & B. thuringiensis, to be held later this month in New Delhi, India. The second is Vaccines R&D-2015, presented by the United Scientific Group, which takes place in Baltimore, MD, in early November. Both venues will feature scientists from industry, academia, government labs and agencies, and non-profit organizations who will gather to discuss new research discoveries and influential therapies, and share best practices relating to vaccine development.

In the first presentation, Dr. Roberts will discuss recent pre-clinical trial results concerning NasoShield™ (formerly AdVAV™), Altimmune's anthrax vaccine candidate. The second talk will examine the impact a particular vaccine platform technology can have on the ability to meet current vaccine challenges. In this presentation, Dr. Roberts will reveal how Altimmune is exploiting two independent and complementary platform technologies to develop vaccines and immunotherapies for influenza, chronic hepatitis B, anthrax, and cancer.

The conference line-up is as follows:

Bacillus ACT 2015, Oct. 27-31
Paper Title: "Single intranasal dose of NasoShield provides protection in a Bacillus anthracis aerosolized spore challenge model in NZW rabbits and cynomolgus macaques".
Co-Authors: V. Krishnan, C. Shoemaker, B.A. Andersen, G.S. Sivko, G.V. Stark, J. Zhang, T. Feng, V.A. Haque, and M. Scot Roberts.

Vaccines R&D-2015, Nov. 2-4
Paper Title: "The right fit: Matching the vaccine platform to the disease indication".
Co-Authors: Bertrand Georges, Vyjayanthi Krishnan, James Francis, Jianfeng Zhang, Katie Anderson, Christine Shoemaker, Ray Feng, and M. Scot Roberts.

About Altimmune
Altimmune is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary platform technologies, Altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Our Densigen™ T-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual's immune system against multiple target antigens instead of just one. Altimmune's RespirVec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. Altimmune's product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current products. www.altimmune.com.